Congress once again has introduced legislation aimed at curbing abusive patent litigation. While there is wide agreement on the desirability of curtailing frivolous threats and suits, there is another critical issue with our nation's patent system that seems overlooked, perhaps even lost, in the debate: how to provide incentives for investment in biotechnology innovation in an era when research and development spending by both government and industry is falling.